Tissue biopsy with pathologically confirmed malignancy is the standard strategy for breast cancer diagnosis and classification, while clinical and microscopic features including stage, histological subtype, grading, and immunohistochemistry (IHC) staining of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and Ki-67 (MKI67), are determined to augment treatment decisions. This evidence concerns the gene MKI67 and breast carcinoma.